ClinicalTrials.gg
RecruitingNCT06169033Updated Aug 3, 2025

Radiomics of Intra-abdominal and Subcutaneous Adipose Tissue Predict the Efficacy of Bariatric Surgery (RISABS)

An observational study in Obesity, Type 2 Diabetes Mellitus and Bariatric Surgery, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity by China-Japan Friendship Hospital — 8 open to participants now, 8 under way, none of them phase 3. Obesity · China-Japan Friendship Hospital.

Started
2024
with 2 others
Observational
5 of 10
3 open now
Registered
1st of 10
by date

Among the 10 studies in Obesity by China-Japan Friendship Hospital, this one is one of 3 that started in 2024, is one of 5 observational ones, and was the 1st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 10 studies in Obesity by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by China-Japan Friendship Hospital, or all of them as a file.
02

Study summary

Using radiomics of intra-abdominal and subcutaneous adipose tissue and clinical features to predict the weight loss efficacy and remission of type 2 diabetes mellitus after bariatric surgery.

Read the detailed description

In this study, the investigator intend to collect abdominal CT from patients who are proposed to undergo bariatric surgery, to extract the radiomics of intra-abdominal fat and subcutaneous fat, and to establish a prediction model for predicting the efficacy of weight loss and remission of type 2 diabetes mellitus at 1 year, 3 years, and 5 years postoperatively, in conjunction with the clinical data.

03

Conditions studied

  • Obesity
  • Type 2 Diabetes Mellitus
  • Bariatric Surgery

Keywords

  • Obesity
  • Type 2 Diabetes Mellitus
  • Radiomics
  • Abdominal adipose
  • Subcutaneous adipose
  • Prediction model
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Obese patients with type 2 diabetes who will undergo bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) and receive abdominal CT scan will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >27.5kg/m2; Type 2 diabetes mellitus; Patients who will undergo bariatric surgery

Exclusion criteria

Exclusion Criteria:

  • Patients without abdominal CT scan; Patients did not undergo sleeve gastrectomy or Roux-en-Y gastric bypass.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Area under curve (AUC) of the weight loss prediction model after 1 year

    This metric shows the discriminatory ability of the radiomic model to predict the probability of inadequate weight loss after 1 year.

    Time frame: 1 year

  2. Area under curve (AUC) of the T2DM remission prediction model after 1 year

    This metric shows the discriminatory ability of the radiomic model to predict the probability of remission of T2DM after 1 year.

    Time frame: 1 year

Secondary outcomes

  1. Area under curve (AUC) of the weight loss prediction model after 3 years

    This metric shows the discriminatory ability of the radiomic model to predict the probability of inadequate weight loss after 3 years.

    Time frame: 3 years

  2. Area under curve (AUC) of the T2DM remission prediction model after 3 years

    This metric shows the discriminatory ability of the radiomic model to predict the probability of remission of T2DM after 3 years.

    Time frame: 3 years

  3. Area under curve (AUC) of the weight loss prediction model after 5 years

    This metric shows the discriminatory ability of the radiomic model to predict the probability of inadequate weight loss after 5 years.

    Time frame: 5 years

  4. Area under curve (AUC) of the T2DM remission prediction model after 5 years

    This metric shows the discriminatory ability of the radiomic model to predict the probability of remission of T2DM after 5 years.

    Time frame: 5 years

  5. Area under curve (AUC) of the weight regain model

    This metric shows the discriminatory ability of the radiomic model to predict the probability of weight regain.

    Time frame: 5 years

  6. Area under curve (AUC) of the T2DM relapse model

    This metric shows the discriminatory ability of the radiomic model to predict the probability of T2DM relapse.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Subject information involves medical and personal privacy and access is subject to the consent of the principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 35 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169033
Responsible party
Yuntao Nie (Principal Investigator, China-Japan Friendship Hospital) — Principal investigator
First posted
Dec 13, 2023
Start date
Jan 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 3, 2025

Study contacts

Yuntao Nie, M.D.
Contact
nytnyt1231@163.com
+8618611835860
Hua Meng, M.D.
Contact
menghuade@hotmail.com
+8618611457779
Yuntao Nie, M.D.
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion